Pregnancy should not greatly alter the anaesthetic management of a patient with intracranial aneurysms. Controlled hypotension is the method of choice for meeting surgical requirements. 9,10 Primary attention to the mother with judicious use of sodium nitroprusside is unlikely to compromise the foetus. 6, 8, 11, 26 Sodium nitroprusside is not teratogenic in animal experiments. 25 At present, the biochemical consequences for the foetus of prolonged nitrous oxide anaesthesia are not clear. Present data would support folinic acid administration. 68, 70 
diuretics in pregnancy stems from rabbit research in which gross foetal dehydration occurred when massive doses of mannitol were given (12 g/kg). 5 A more conservative 1 g/kg or less has not proved detrimental. 6, 7, 8 Currently, controlled hypotension, usually employing sodium nitroprusside (SNP), is the commonest method of facilitating aneurysm clipping. 9, ID In 1979, Minielly et al. I reported a series of eight pregnant patients of whom six, in the third trimester, qualified for surgical clipping of their aneurysms. Surgery was facilitated by controlled hypotension (trimetaphan the recommended agent) with good results. Subsequently, there have been three reports 6 , 8, 11 of four instances of successful management of pregnant aneurysm patients using halothane and SNP.
Pregnancy considerations
There are many considerations relating to anaesthesia in pregnancy. 12 Oxygenation may be at risk during induction because of the increased ventilatory demands of pregnancyl2 and throughout periods of induced hypotension. 13, 14 Anaesthetics have a potential for teratogenicity, the most critical period in man being the time of organogenesis which is from two to eight weeks. 12 Halothane would seem to be safe and may offer the additional advantage of improving uterine blood flow (UBF) in the face of moderate maternal hypotension. IS Nitrous oxide, though widely used, has been shown to be teratogenic and foetotoxic in laboratory animals. 16 ,17 Reduced DNA synthesis, as a consequence of vitamin B12 oxidation by nitrous oxide, may be the basis for this. 16 ,17 
Hypotension and pregnancy
The perfusion pressure is the main factor determining UBF 12 ,13 unless for some reason there is an alteration in uterine muscle tone or vascular resistance.
Halothane and isoflurane at 1.0 and 1.5 MAC in near-term sheep allow utero-placental flow to be maintained in the face of a 15-25% fall in mean arterial pressure (MAP).IS However, with 2 MAC halothane, the profound (greater than 35070) fall in MAP reduced UBF by approximately 20% despite vasodilation and uterine muscle relaxation. The consequent foetal hypoxia and acidosis were reversible. SNP may also have a sparing effect on UBF. 18 , 19 Experimenting with sheep, Assali and Brinkman 13 report that foetal hypoxia can trigger protective responses such as dilation of the ductus arteriosus and vasoconstriction of the pulmonary vessels with increased right-toleft flow through the foramen ovale. Thus, the foetus can tolerate an impaired oxygen supply but its compensatory mechanisms are limited.
Foetal heart monitoring is a very useful way of gauging the foetal response to hypoxia 20 or to induced hypotension. I Tachycardia and loss of the normal variability of the beat-to-beat interval are usually the first signs of foetal compromise. 20 Foetal bradycardia results from severe maternal hypotension. 1,6
Later in pregnancy (when haemorrhage from aneurysms more commonly presents) the safety margins for induced hypotension may be narrower because of the greater metabolic requirements of the foetus. The anaesthetist may need assistance in continuous foetal heart monitoring, for maternal AGA and blood glucose sampling. However, foetal heart rate monitoring, while reassuring if normal, must not distract from overall management.
SNP in pregnancy
The use of SNP in obstetrics is controversial. 21 The potential for foetal cyanide toxicity is the main objection while diminution of UBF is a further consideration.
Wheeler et al. 19 (using 3 J.lg/kg/min) and Naulty et al. 18 (1-25 J.lg/kg/min) reported no significant alteration in UBF in gravid sheep when MAP was reduced by 20%. Results from Lieb et al. 22 differ: using SNP at 1-10 J.lg/kg/min, UBF fell proportionately with a MAP reduction of up to 30%. This group measured flow with a transducer around the common internal iliac artery.
Using gravid sheep, Naulty et al. 18 infused SNP into eight animals to reduce MAP by 20% for one hour. Three ewes requiring low infusion rates (less than 1 J.lg/kg/min) survived with their foetuses. The other five requiring progressively higher SNP dosage (mean 25 J.lg/kg/min) died, foetal death preceding ewe death. Blood cyanide (CN) levels were low in survivors -less than 50 J.lg/dl in both ewe and foetus. In contrast, CN levels in non-survivors were three to four times greater at one hour. In addition (using an indirect method)23 plasma SNP levels were measured in both ewe and foetus, with the conclusion that "the nitroprusside molecule readily crosses the placenta".18 It was found that "there was no significant difference in nitroprusside levels between survivors and non-survivors" as distinct from CN levels.
In contrast are two articles from German literature. Madder et al. 24 examined the autoradiographic distribution of CI4 after giving tracer marked SNP, CN and thiocyanate (SCN) to pregnant mice and rats (dose ranges 1.5-3 mg/kg). Autoradiograms were taken at 1, 10 and 60 minutes. Strong lung, kidney and liver markings seen at 1 and 10 minutes after labelled CN and SNP suggest elimination of prussic acid (HCN) from the lungs and rapid renal excretion and liver metabolism. No foetal markings were seen until 60 minutes after the SNP. They concluded that in the doses used SNP does not cross the placenta in measurable Anaesthesia and If11ensive Care, Vol. 12, No. 4, November, 1984 amounts, that some CN does and that SCN crosses freely. Possible support for SNP not crossing the placenta is offered by Ivankovic 25 who showed that there was no evidence of embryotoxic or teratogenic effects from SNP in either rats or rabbits. High daily intravenous doses of SNP were given from the time of conception (rabbits 70070 LD50, rats 43070 and 54070 LDso).
Further confirmation of the lack of morbidity of low dose SNp I8 is given by Ellis et al. 26 who used SNP to reverse the 20070 blood pressure rise resulting from a noradrenaline infusion into gravid ewes. No foetal or maternal compromise occurred with SNP at 2.3 /-lg/kg/min. Foetal AGA were acceptable after 50 minutes. Foetal and maternal blood CN levels were low -less than 50 /-lg/l. (These were measured with a CN ion-sensing electrode which Kistner et al. 27 have shown to lack sensitivity for use in biological fluids.)
Species differences may account partly for the conflict in results: SNP LD so (mg/kg IV) for rats is 11.2 while for rabbits it is 2.8. 28 Compounds with a molecular weight (mol wt) below 600 readily cross the placenta (SNP = 298). 29 The short half-life of SNP in rats may account for its apparent failure to cross 24 and the lack of foetotoxicity. 25 While on a molecular weight basis one would expect SNP to cross the placenta, there is no available data on lipid solubility, pKa or half-life 28 because there is no direct assay for SNP. 30 Clinically, the half-life in man appears to be short. 28 Provided the rate of infusion does not exceed 10 JAg/kg/min, conversion to CN will keep blood SNP levels low. 23 While some CN crosses the placenta,24 the only report of toxic foetal levels comes from Naulty et al. 18 who demonstrated foetal CN enrichment with sustained high dosage in sheep (25 /-lg/kg/min). Any maternal SCN generated will cross the placenta freely. 24, 31 Recently, controversy32-28 has been precipitated by Bisset et al. 32 ,33 who have only been able to duplicate the in vitro findings of earlier workers if analyses were performed in light. They believe 'SNP does not liberate CN on contact with any fraction of blood, nor does it react with haemoglobin.'33 Two aspects of interest emerge: the validity of CN assays in blood also containing SNP is questionable 32 ,33
Anaesthesia and Intensive Care, Vol. 12, No. 4, November, 1984 and the opinion that SNP solutions should be rigorously protected from both sun and artificial light. 32 In criticism, the light challenge used was extreme and there was no examination of ambient theatre lighting. However, manufacturers are now recommending prompt light protection to ensure stability of SNP solutions. 28 ,30 Regardless of the mechanism of in vivo SNP breakdown, 10,39-41 once CN is formed the major detoxification pathway involves thiosulphate (Na2S203) as an S donor and the mitochondrial enzyme rhodanase to yield SCN. The availability of thiosulphate is the limiting factor in adults, not the supply of rhodanase. 41 Limited thiosulphate production has been found in children;42 presumably the foetus is in a similar position with the possible added limitation of hepatic immaturity. 6
There has been no evaluation of whether continuous infusion of CN antidotes thiosulphate 43 ,44 or hydroxocobalamin 45 ,46 can protect a pregnant animal and its foetus from the effects of excessive SNP infusion. Hydoxocobalamin and CN yield cyanocobalamin which is rapidly excreted in the urine. 45 This gives hydroxocobalamin a theoretical advantage as any resultant SCN crosses the placenta and has a long half-life of 3.6 days.28 Large doses of thiosulphate could cause dehydration through osmotic diuresis. 42 ,43 Human experiences Short-term SNP infusion has been used successfully to manage obstetric hypertensive crises. 47 Stempel et al. 47 observed no sign of foetal distress with lowering of blood pressure. Where measured, cord CN was very low but the assay method was not stated.
Neurosurgery
Clinical reports are summarised in Table 1 . Foetal and maternal results were satisfactory in each of the above cases, supporting the use of SNP in this context.
Clinical considerations
Deep general anaesthesia,41 halothane 48 and, occasionally, small doses of beta-adrenergic blocking drugs 49 ,50 have been shown to reduce requirement for SNP. The use of beta-blockers during pregnancy has been associated with myometrial irritability and a variety of foetal problems including bradycardia, hypotension, If resistance to SNP is encountered, additional measures must be introduced or an alternative agent sought rather than risk foetal CN toxicity. Increased halothane, trimetaphan, hydrallazine, nitroglycerin and beta-blockers are some options. Large doses of long-acting hypotensive agents are better avoided as once the aneurysms is clipped the blood pressure should return to normal without overshoot.
Hydrallazine HCI (mol wt 160) has been used in obstetrics without foetal compromise. 51 A dose of 4-8 mg may be sufficient. Large doses may be associated with significant placental transfer. 55 Nitroglycerin (mol wt 227) crosses the placenta because of its low mol wt and uncharged state. While it has been used briefly during caesarean sections,56 insufficient is known about its foetal metabolism to recommend prolonged use. Its effect on UBF is similar to SNP. 19 Trimetaphan Labetalol HCI (mol wt 365), when released for intravenous use in this country, may have a place. 59 Clinical studies support its use in the second and third trimester despite a high degree of placental transfer. 53
Vitamin BJ2
There are numerous reasons why vitamin B12 supply and function may be compromised in such pregnant aneurysm patients. Smoking,60 pregnancy,61 and SNP infusion itself,62,63 are associated with reduced blood vitamin B12 levels. Also nitrous oxide oxidises vitamin B12. 64 . 66 The biochemical effects of nitrous oxide are similar to untreated B12 deficiency in man. 66 The most sensitive index of this action of nitrous oxide is methionine synthetase activityY The vitamin B12 cofactor of this intracellular enzyme is oxidised irreversibly and recovery (in rodents) takes at least three days.16.64,68 As a result there is reduced methionine regeneration from homocysteine and a functional folate deficiency identical with the 'methyl folate trap' situation seen in pernicious anaemia. 66·69
According to Sullivan et al.,68 nitrous oxide anaesthesia of less than six hours' duration does not produce megaloblastic changes in human bone marrow nor reduce DNA biosynthesis (as measured by the deoxyuridine suppression test). These changes are seen after twelve hours' exposure to nitrous oxide and spontaneously recover within twelve hours.68 However, ill intensive care patients after only 1-6 hours anaesthesia show severe changes in the bone marrow and recovery is considerably prolonged when compared with Sullivan's group. 70 Pre-and intra-operative folinic acid will prevent these changes in most patients. 68 ,70 It needs to be given in large doses (40-60 mg) to be effective and preferably given preoperatively (1 and 12 hours before anaesthesia, orally) as nitrous oxide interferes with folinic acid uptake either by directly inactivating it or preventing uptake into cells. 70 Methionine is classed as an essential amino acid and hence the inactivation of methionine synthetase should not affect supply. However, serum methionine falls within one hour of nitrous oxide anaesthesia and is still low twenty-four hours later. 71.72 Some consider that despite an adequate dietary supply of methionine, the remethylation of homocysteine is important because of the major turnover of methionine as a methyl group donor. 67,17,7J Methionine is essential for the maintenance of normal neural myelination. 74 Vitamin BI2 and folic acid are dietary essentials in man and deficiency of either may impair DNA synthesis and compromise cell division. 69 Consideration should be given to supplementary vitamin BI2 to compensate for dietary insufficiency during hospitalisation. 8 Current information strongly supports the use of folinic acid in pregnant patients undergoing prolonged anaesthesia with nitrous oxide. Oral methionine could also be considered. It may be better to avoid nitrous oxide early in pregnancy.
